1. EDINBURGH, United Kingdom, Feb. 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in the following conferences:

    Cowen 41st Annual Health Care Conference
    Presentation Date: Thursday, March 4, 2021
    Presentation Time: 1:30 PM ET

    H.C. Wainwright Global Life Sciences Conference
    Dates: March 9-10, 2021

    Oppenheimer's 31st Annual Healthcare Conference
    Presentation Date: Thursday, March 18, 2021
    Presentation Time: 9:20 AM ET

    The presentations at the Cowen 41st Annual Health Care Conference and Oppenheimer's 31st Annual Healthcare Conference will be webcast live. Both presentations will be available for replay under "Events & Presentations…

    EDINBURGH, United Kingdom, Feb. 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in the following conferences:

    Cowen 41st Annual Health Care Conference

    Presentation Date: Thursday, March 4, 2021

    Presentation Time: 1:30 PM ET

    H.C. Wainwright Global Life Sciences Conference

    Dates: March 9-10, 2021

    Oppenheimer's 31st Annual Healthcare Conference

    Presentation Date: Thursday, March 18, 2021

    Presentation Time: 9:20 AM ET

    The presentations at the Cowen 41st Annual Health Care Conference and Oppenheimer's 31st Annual Healthcare Conference will be webcast live. Both presentations will be available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies, including NuTide:121; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith

    Chief Executive Officer

    NuCana plc

    Tel: +44 131 357 1111

    Westwicke, an ICR Company

    Chris Brinzey

    Tel: +1 339-970-2843

    RooneyPartners

    Marion Janic

    Tel: +1 212-223-4017



    View Full Article Hide Full Article
  2. Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy

    Safety Profile Continues to be Favorable

    EDINBURGH, United Kingdom, Jan. 15, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.

    NuTide:302 is a three-part study investigating NUC-3373, NuCana's targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer. The study is evaluating NUC-3373's optimal dose and schedule in combination with agents commonly used to treat patients with colorectal cancer and is assessing safety…

    Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy

    Safety Profile Continues to be Favorable

    EDINBURGH, United Kingdom, Jan. 15, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) today announced interim data from the ongoing NuTide:302 study at the ASCO GI Conference, being held virtually January 15-17, 2021.

    NuTide:302 is a three-part study investigating NUC-3373, NuCana's targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer. The study is evaluating NUC-3373's optimal dose and schedule in combination with agents commonly used to treat patients with colorectal cancer and is assessing safety, pharmacokinetics and anti-cancer activity. NUC-3373 has been designed to overcome the main challenges associated with 5-FU and capecitabine, including cancer-resistance mechanisms which limit efficacy, off-target toxicity and administration burdens.

    The ASCO GI presentation highlighted data from 37 patients treated in Part I of the study who received NUC-3373 either as monotherapy or in combination with leucovorin. Ten patient case studies highlighted NUC-3373's ability to stabilize disease and achieve prolonged durations of progression-free survival. Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of therapy and five patients experienced tumor shrinkage. These patients included:

    • A fourth-line patient who achieved a Partial Response with a 40% reduction in tumor volume;
    • A third-line patient who achieved a 28% reduction in tumor volume after their disease rapidly progressed through all prior fluoropyrimidine-containing regimens.

    Among the efficacy-evaluable population, a disease control rate of 62% was achieved.

    In addition to these encouraging efficacy signals, the presentation compared the safety profile of NUC-3373 in Part I of the study with historical data for 5-FU and capecitabine in the front-line treatment of patients with colorectal cancer. NUC-3373 was well tolerated with no hand-foot-syndrome or neutropenia as well as lower rates of diarrhea, mucositis and stomatitis.

    Dr. Andrew Coveler, Associate Professor at the University of Washington School of Medicine and Fred Hutchinson Cancer Research Center and an investigator in the NuTide:302 study, remarked: "I am encouraged by both the clinical activity and safety of NUC-3373. To observe this anti-cancer activity, including a Partial Response, in such a heavily pre-treated patient population is very promising. In addition, NUC-3373 has been well tolerated and its safety appears favorable when compared to 5-FU and capecitabine. As such, I look forward to advancing NUC-3373's development in patients with colorectal cancer."

    "We are very pleased with these additional data from Part I of the NuTide:302 study," said Hugh S. Griffith, NuCana's Founder and CEO. "It was particularly encouraging to observe tumor shrinkages, prolonged disease stabilization and a favorable safety profile in a patient population that had received at least two prior fluoropyrimidine-containing regimens. We look forward to continuing Part II of the study in which NUC-3373 is being combined with leucovorin and either oxaliplatin or irinotecan. Our objective is to replace 5-FU and capecitabine with NUC-3373 as the backbone of treatment for patients with colorectal cancer."

    Details of the poster presentation are as follows:

     Title: A phase Ib study of NUC-3373 in combination with standard therapies in

    advanced/metastatic colorectal cancer (NuTide:302) 

    Session: Colorectal Cancer

    Abstract Number: 93

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is in a Phase III study for patients with advanced biliary tract cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies, including NuTide:121; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:



    View Full Article Hide Full Article
  3. Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors

    Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics

    EDINBURGH, United Kingdom, Dec. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Andrew Kay as Chairman of its Board of Directors.

    "We are delighted to welcome Andrew as NuCana's Board Chairman," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Andrew is an internationally recognized executive and brings a wealth of leadership experience at several successful biotechnology and pharmaceutical…

    Pharmaceutical Executive Brings a Wealth of Experience to NuCana's Board of Directors

    Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics

    EDINBURGH, United Kingdom, Dec. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Andrew Kay as Chairman of its Board of Directors.

    "We are delighted to welcome Andrew as NuCana's Board Chairman," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "Andrew is an internationally recognized executive and brings a wealth of leadership experience at several successful biotechnology and pharmaceutical companies. His track record of building shareholder value throughout his career, along with his experience taking compounds through development and commercialization will bring significant value to NuCana. We look forward to working with Andrew as we advance our ProTide pipeline."

    Andrew Kay said, "I look forward to serving as Chairman of NuCana's Board as we leverage our ProTide technology platform with the aim of developing more efficacious and better tolerated medicines for patients with cancer. With several important ongoing clinical studies and numerous upcoming data announcements, I believe this is an exciting time to be joining NuCana's Board."

    Andrew Kay brings more than 30 years of experience in building and leading biotechnology and pharmaceutical companies. Andrew currently serves as Chairman of the Board of NeRRe Therapeutics and Blueberry Therapeutics. He also recently held the same role for KaNDy Therapeutics, a biotechnology company that was acquired by Bayer for a deal value of up to $875 million in 2020, and for Wilson Therapeutics, a biopharmaceutical company acquired by Alexion Pharmaceuticals for $855 million in 2018. Prior to that, Andrew served as the President and Chief Executive Officer for Algeta. During Andrew's leadership, Algeta's lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration-resistant prostate cancer patients, followed by a strong commercial launch. In February 2014, Algeta was acquired by Bayer AG for $2.9 billion. Prior to Algeta, Andrew was the Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and held several other senior commercial positions in Europe and the US having worked at AstraZeneca, Eli Lilly, Sandoz and Boots.

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical studies, including a Phase III study for patients with advanced biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies, including NuTide:121; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:



    View Full Article Hide Full Article
  4. Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed

    NuTide:121 Global Phase III Study Recruitment Ongoing

    EDINBURGH, United Kingdom, Nov. 30, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced that the final results of the Phase Ib study of Acelarin plus cisplatin for patients with advanced biliary tract cancer (ABC-08) have been published online ahead of print in The Oncologist. Encouraging interim data had previously been reported and the final data confirm the high objective response rate and favorable safety profile of Acelarin plus cisplatin in this patient population.

    In the efficacy-evaluable patient population, the Objective Response Rate was 44%. By comparison, in the ABC-02 study…

    Acelarin plus Cisplatin's High Objective Response Rate and Favorable Safety Profile Confirmed

    NuTide:121 Global Phase III Study Recruitment Ongoing

    EDINBURGH, United Kingdom, Nov. 30, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced that the final results of the Phase Ib study of Acelarin plus cisplatin for patients with advanced biliary tract cancer (ABC-08) have been published online ahead of print in The Oncologist. Encouraging interim data had previously been reported and the final data confirm the high objective response rate and favorable safety profile of Acelarin plus cisplatin in this patient population.

    In the efficacy-evaluable patient population, the Objective Response Rate was 44%. By comparison, in the ABC-02 study, which led to gemcitabine plus cisplatin becoming the current standard of care for the first-line treatment of patients with advanced biliary tract cancer, an Objective Response Rate of 26% was achieved in the efficacy-evaluable population.

    Dr. Mairéad McNamara, Co-Chief Investigator of the ABC-08 study and Senior Lecturer and Honorary Consultant in Medical Oncology at the University of Manchester and The Christie NHS Foundation Trust remarked: "Acelarin combined with cisplatin demonstrated a favorable safety profile and achieved good tumor control. Responses were seen across all five biliary tract cancer sub-types, including a Complete Response in one patient, a very rare occurrence in this patient population. In ABC-02, only one out of 161 efficacy-evaluable patients who received gemcitabine plus cisplatin achieved a Complete Response. Additionally, one patient with Stable Disease, whose tumor had initially been considered unsuitable for surgical resection, was able to have complete surgical removal of the tumor following treatment with Acelarin plus cisplatin. Four patients were still alive at the end of follow-up, having survived between 16 and 36 months."

    "We are very encouraged by the final efficacy and safety data from ABC-08", said Hugh S. Griffith, NuCana's founder and CEO. "We are committed to developing Acelarin plus cisplatin as the first approved front-line treatment for patients with advanced biliary tract cancer. We continue to drive recruitment in the ongoing Phase III NuTide:121 Study where we believe we have the potential opportunity to apply for accelerated approval based on Objective Response Rate. We remain on track to enroll the required number of patients in NuTide:121 by the end of 2021 in order to conduct the first interim analysis in 2022."

    Professor Juan Valle, Co-Chief Investigator of the ABC-02, ABC-08 and NuTide:121 studies and Professor and Honorary Consultant in Medical Oncology at the University of Manchester and The Christie NHS Foundation Trust said: "Biliary tract cancer is a devastating disease for which more effective treatments are desperately needed. While targeted therapies and immunotherapies may play a role in the treatment of biliary tract cancer in the future, chemotherapy will remain the backbone of treatment. Medicines like Acelarin, with the potential for improved efficacy and safety, would be welcome additions to the treatment options for patients with biliary tract cancer."

    About NuTide:121

    NuTide:121 is a global, multi-center, randomized Phase III study that is enrolling up to 828 patients in approximately 130 sites across North America, Europe, Asia and Australia. Patients are being randomized 1:1 and treated with either a combination of Acelarin (725 mg/m2) plus cisplatin (25 mg/m2) or the current standard of care regimen, gemcitabine (1,000 mg/m2) plus cisplatin (25 mg/m2). The primary objectives of NuTide:121 are Overall Survival (OS) and Objective Response Rate (ORR). Three interim analyses, including two designed to support accelerated approval, are planned as part of the Phase III study protocol, in addition to the final analysis. Based on discussions with the FDA and subject to any further regulatory guidance, the Company believes that a statistically significant improvement in ORR at either of the first two interim analyses, supported by positive trends in other endpoints, could potentially allow for an accelerated approval of a new drug application (NDA) for Acelarin. Accelerated approval requires a confirmatory clinical study to verify the drug's clinical benefit. If accelerated approval were to occur, NuTide:121 would continue and the Company anticipates that data from subsequent analyses could provide the confirmatory data to support full (regular) approval.

    About Biliary Tract Cancer

    Biliary tract cancer, including cholangiocarcinoma, gallbladder and ampullary carcinoma, is cancer originating in the bile duct, a vessel that transports bile from the liver to the gallbladder and small intestine. Approximately 178,000 new cases of biliary tract cancer are diagnosed each year worldwide, with more than 18,000 of those diagnoses in the United States. There are currently no agents approved for the treatment of biliary tract cancer; however, the worldwide standard of care in the first-line setting for patients with advanced biliary tract cancer is the combination of gemcitabine and cisplatin.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical studies, including a Phase III study for patients with advanced biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of patients with advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies, including NuTide:121; the potential for accelerated approval of Acelarin; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

     For more information, please contact:

    Hugh S. Griffith

    Chief Executive Officer

    NuCana plc

    Tel: +44 131 357 1111

    Westwicke, an ICR Company

    Chris Brinzey

    Tel: +1 339-970-2843

    RooneyPartners

    Marion Janic

    Tel: +1 212-223-4017



    View Full Article Hide Full Article
  5. Completed Successful $80 million Public Offering

    Presented Encouraging Data for NUC-3373 and NUC-7738 at the ESMO Virtual Congress 2020

    EDINBURGH, United Kingdom, Nov. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the third quarter ended September 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of September 30, 2020, NuCana had cash and cash equivalents of £100.7 million compared to £47.8 million at June 30, 2020 and £52.0 million at December 31, 2019. This cash balance includes the net proceeds from NuCana's public offering in September 2020. NuCana continues to advance its various clinical programs and reported a net loss of £8.4 million…

    Completed Successful $80 million Public Offering

    Presented Encouraging Data for NUC-3373 and NUC-7738 at the ESMO Virtual Congress 2020

    EDINBURGH, United Kingdom, Nov. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the third quarter ended September 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of September 30, 2020, NuCana had cash and cash equivalents of £100.7 million compared to £47.8 million at June 30, 2020 and £52.0 million at December 31, 2019. This cash balance includes the net proceeds from NuCana's public offering in September 2020. NuCana continues to advance its various clinical programs and reported a net loss of £8.4 million for the quarter ended September 30, 2020, as compared to £3.9 million for the quarter ended September 30, 2019. Basic and diluted loss per share was £0.24 for the quarter as compared to £0.12 per share for the prior-year quarter.

    "We are very pleased with our achievements during the third quarter," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "We significantly augmented our financial position with the successful completion of this public offering, supporting our progress towards several important milestones. These milestones include filing a New Drug Application ("NDA") for Acelarin in biliary tract cancer, filing an NDA for NUC-3373 in colorectal cancer, and completing a Phase II clinical study for NUC-7738, in each case subject to regulatory feedback and clinical outcomes."

    Mr. Griffith continued: "We also presented encouraging data at the ESMO Virtual Congress 2020, including a poster highlighting interim data from the ongoing Phase Ib study of NUC-3373 in combination with other agents typically combined with 5-FU in patients with advanced colorectal cancer (NuTide:302) and a poster detailing the first-ever clinical data from the ongoing Phase I study of NUC-7738 in patients with advanced solid tumors (NuTide:701). We believe the data from the NuTide:302 study support the potential of NUC-3373 to improve progression-free survival in patients who had relapsed or were refractory to prior 5-FU-containing regimens. We also believe these data show NUC-3373's potential to offer enhanced efficacy, an improved safety profile and a more convenient dosing regimen as compared to 5-FU. With respect to NUC-7738, we believe the interim data from the NuTide:701 study demonstrate that NUC-7738 has a favorable pharmacokinetic and tolerability profile and is showing encouraging anti-cancer activity."

    Mr. Griffith concluded, "We continue to drive recruitment in all of our ongoing studies and remain focused on our mission of developing safer and more effective medicines for patients with cancer."

    Anticipated 2021 Milestones

    • Acelarin is a ProTide transformation of gemcitabine. In 2021, NuCana expects to:



      °  Complete recruitment to enable the first interim analysis of the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.



    • NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-FU. In 2021, NuCana expects to:



      °  Report data from the Phase Ib study (NuTide:302) of NUC-3373 in combination with other agents with which 5-FU is typically combined, such as leucovorin, oxaliplatin and irinotecan in patients with advanced colorectal cancer.

      °  Initiate and report data from a Phase Ib expansion / Phase II study of NUC-3373 in combination with other agents for patients with colorectal cancer.

      °  Initiate a Phase III study of NUC-3373 in combination with other agents for patients with colorectal cancer.

      °  Report data from the ongoing Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors.
    • NUC-7738 is a ProTide transformation of a novel nucleoside analog, 3'-deoxyadenosine. In 2021, NuCana expects to:



      °  Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors.

      °  Initiate a Phase II study of NUC-7738 in patients with solid tumors.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the sufficiency of the Company's current cash and cash equivalents; the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the fact that the Company's expectations as to the sufficiency of the Company's current cash and cash equivalents to fund its planned operations excludes any potential costs related to pre-commercial activities or, if approved, commercialization costs, as well as the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.





    Unaudited Condensed
    Consolidated Statements of Operations

          
     For the three months ended

    September 30,

     For the nine months ended

    September 30,
     
     2020 2019  2020 2019 
     (in thousands, except per share data)
     £ £  £ £ 
              
    Research and development expenses(6,117)(4,845) (17,918)(14,551)
    Administrative expenses(1,906)(1,423) (5,144)(4,231)
    Net foreign exchange (losses) gains(1,601)1,227  610 1,191 
    Operating loss(9,624)(5,041) (22,452)(17,591)
    Finance income26 252  234 867 
    Loss before tax (9,598)(4,789) (22,218)(16,724)
    Income tax credit1,204 912  3,797 3,020 
    Loss for the period(8,394)(3,877) (18,421)(13,704)
              
              
    Basic and diluted loss per share(0.24)(0.12) (0.55)(0.42)
          





    Unaudited Condensed
    Consolidated Statements of Financial Position

     September 30,

    2020
     December 31,

    201
    9
     
     (in thousands)
     £ £ 
    Assets  
    Non-current assets  
    Intangible assets4,686 3,960 
    Property, plant and equipment1,281 1,109 
    Deferred tax asset34 46 
     6,001 5,115 
    Current assets  
    Prepayments, accrued income and other receivables5,065 4,710 
    Current income tax receivable8,140 8,481 
    Cash and cash equivalents100,678 51,962 
     113,883 65,153 
    Total assets119,884 70,268 
    Equity and liabilities  
    Capital and reserves  
    Share capital and share premium142,937 80,840 
    Other reserves65,740 62,737 
    Accumulated deficit(98,403)(80,055)
    Total equity attributable to equity holders of the Company110,274 63,522 
       
    Non-current liabilities  
    Provisions46 26 
    Lease liabilities441 538 
     487 564 
       
    Current liabilities  
    Trade payables4,190 2,412 
    Payroll taxes and social security138 160 
    Lease liabilities278 268 
    Accrued expenditure4,517 3,342 
     9,123 6,182 
       
    Total liabilities9,610 6,746 
       
    Total equity and liabilities119,884 70,268 
         





    Unaudited Condensed
    Consolidated Statements of Cash Flows

     For the nine months ended

    September 30,
     2020 2019 
     (in thousands)
     £ £ 
    Cash flows from operating activities  
    Loss for the period(18,421)(13,704)
    Adjustments for:  
    Income tax credit(3,797)(3,020)
    Amortization and depreciation667 522 
    Finance income(234)(867)
    Interest expense on lease liabilities20 - 
    Share-based payments3,069 2,191 
    Net foreign exchange gains(619)(1,228)
     (19,315)(16,106)
    Movements in working capital:  
    Increase in prepayments, accrued income and other receivables(408)(3,593)
    Increase (decrease) in trade payables1,778 (300)
    Increase in payroll taxes, social security and accrued expenditure1,153 8 
    Movements in working capital2,523 (3,885)
    Cash used in operations(16,792)(19,991)
    Net income tax received4,152 20 
    Net cash used in operating activities(12,640)(19,971)
    Cash flows from investing activities  
    Interest received300 915 
    Payments for property, plant and equipment(350)(29)
    Payments for intangible assets(1,079)(988)
    Net cash used in investing activities(1,129)(102)
    Cash flows from financing activities  
    Payments of lease liabilities(223)(146)
    Proceeds from issue of share capital – exercise of share options15 117 
    Proceeds from issue of share capital66,581 - 
    Share issue expenses(4,499)- 
    Net cash from (used in) financing activities 61,874 (29)
    Net increase (decrease) in cash and cash equivalents48,105 (20,102)
    Cash and cash equivalents at beginning of period51,962 76,972 
    Effect of exchange rate changes on cash and cash equivalents611 1,221 
    Cash and cash equivalents at end of period100,678 58,091 
         





    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:

     



    View Full Article Hide Full Article
  6. EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020.

    Event: Piper Sandler 32nd Annual Healthcare Conference
    Pre-Recorded Presentation Replay: November 23, 2020 – December 3, 2020

    The presentation will be pre-recorded and available for replay starting Monday, November 23, 2020 at 10:00 AM ET under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company…

    EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020.

    Event: Piper Sandler 32nd Annual Healthcare Conference

    Pre-Recorded Presentation Replay: November 23, 2020 – December 3, 2020

    The presentation will be pre-recorded and available for replay starting Monday, November 23, 2020 at 10:00 AM ET under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith

    Chief Executive Officer

    NuCana plc

    Tel: +44 131 357 1111

    Westwicke, an ICR Company

    Chris Brinzey

    Tel: +1 339-970-2843

    RooneyPartners

    Marion Janic

    Tel: +1 212-223-4017



    View Full Article Hide Full Article
  7. EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual London Healthcare Conference.

    Event: Jefferies Virtual London Healthcare Conference
    Presentation Date: Wednesday, November 18, 2020
    Presentation Time: 11:45 AM GMT

    The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide…

    EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual London Healthcare Conference.

    Event: Jefferies Virtual London Healthcare Conference

    Presentation Date: Wednesday, November 18, 2020

    Presentation Time: 11:45 AM GMT

    The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith

    Chief Executive Officer

    NuCana plc

    Tel: +44 131 357 1111

    Westwicke, an ICR Company

    Chris Brinzey

    Tel: +1 339-970-2843

    RooneyPartners

    Marion Janic

    Tel: +1 212-223-4017

    View Full Article Hide Full Article
  8. EDINBURGH, United Kingdom, Oct. 13, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Bali Muralidhar, M.D., Ph.D. to its Board of Directors.

    "We are delighted to welcome Bali to NuCana's Board," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is internationally recognized for his investing acumen in the life sciences sector and we believe his financial and clinical experience will bring significant value to NuCana as we advance our ProTide pipeline. We believe Abingworth's decision to make a substantial investment in NuCana as part of our recent successful public offering further…

    EDINBURGH, United Kingdom, Oct. 13, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Bali Muralidhar, M.D., Ph.D. to its Board of Directors.

    "We are delighted to welcome Bali to NuCana's Board," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "He is internationally recognized for his investing acumen in the life sciences sector and we believe his financial and clinical experience will bring significant value to NuCana as we advance our ProTide pipeline. We believe Abingworth's decision to make a substantial investment in NuCana as part of our recent successful public offering further validates the potential of our ProTides to transform the treatment of patients with cancer. We were pleased that we were able to attract several new specialist healthcare investors to this financing in addition to the significant support from our existing investors. This financing will enable NuCana to advance the development of our ProTides and achieve several important milestones."

    Dr. Muralidhar said, "We are excited to be a substantial new investor in NuCana. I look forward to serving on the NuCana Board as they leverage their ProTide technology platform to develop more efficacious and safer medicines for patients with cancer."

    About Abingworth

    Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams and building world-class companies. Since 1973, Abingworth has invested in 167 life science companies, leading to more than 40 M&A/exits and close to 70 IPOs. Abingworth's therapeutic focused investments fall into 3 categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California) and Boston.

    About NuCana

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:

    View Full Article Hide Full Article
  9. Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)

    NUC-3373's Favorable Pharmacokinetic and Safety Profile Unaffected by Leucovorin

    First-in-Human Data of NUC-7738 Shows Anti-Cancer Activity and a Favorable Tolerability Profile

    EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), announced data from the ongoing NUC-3373 and NUC-7738 clinical programs, as well as a review of the ongoing Acelarin Phase III study, at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.

    • NUC-3373 is NuCana's targeted inhibitor of thymidylate synthase designed to overcome the main challenges associated…

    Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)

    NUC-3373's Favorable Pharmacokinetic and Safety Profile Unaffected by Leucovorin

    First-in-Human Data of NUC-7738 Shows Anti-Cancer Activity and a Favorable Tolerability Profile

    EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA), announced data from the ongoing NUC-3373 and NUC-7738 clinical programs, as well as a review of the ongoing Acelarin Phase III study, at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.

    • NUC-3373 is NuCana's targeted inhibitor of thymidylate synthase designed to overcome the main challenges associated with 5-FU including cancer resistance mechanisms, off-target toxicity and administration burdens. Data from the ongoing Phase Ib study (NuTide:302) in heavily pre-treated patients with metastatic colorectal cancer demonstrated NUC-3373's favorable pharmacokinetic and tolerability profile was unaffected by leucovorin. Six case studies highlighted NUC-3373's ability to stabilize disease and achieve encouraging durations of progression-free survival in patients who had relapsed or were refractory to prior 5-FU-containing regimens. Some patients maintained stable disease for a longer period of time on NUC-3373 than they had on their prior line of therapy and some patients experienced tumor shrinkage, including one fluoropyrimidine-refractory patient. NuCana believes these data support the potential of NUC-3373 to improve progression-free survival in patients who had relapsed or were refractory to prior 5-FU containing regimens. NuCana also believes these data show NUC-3373's potential to offer enhanced efficacy, an improved safety profile and a more convenient dosing regimen as compared to 5-FU.



    • NUC-7738 is NuCana's transformation of a novel nucleoside analog, 3'-deoxyadenosine or 3'-dA. NUC-7738, which has several potential modes of action, is being evaluated in a Phase I study (NuTide:701) in patients with advanced solid tumors who have exhausted all standard therapies. Interim data from the study has indicated a favorable pharmacokinetic and tolerability profile of NUC-7738. Additionally, interim data from two case studies showed the significant reductions in tumor volume were maintained over time in these patients. There was also a positive change in the characteristics of a target lesion of one of the patients in the study. NuCana believes these data demonstrate that NUC-7738 has anti-cancer activity.



    • Acelarin (NUC-1031) is a ProTide transformation of gemcitabine being studied as a first-line treatment for patients with advanced biliary tract cancer (BTC). The poster presented at ESMO provides an overview of the ongoing global Phase III study currently being conducted at approximately 100 sites across North America, Europe and Asia Pacific.



    "These latest data further support our belief that our ProTides have the potential to replace the standard of care for patients across a variety of different cancer indications," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "We look forward to announcing data from Part 2 of NuTide:302, which is currently investigating NUC-3373 plus leucovorin in combination with oxaliplatin or irinotecan, and initiating a registrational program in patients with colorectal cancer."

    Mr. Griffith continued: "These first-in-human data from our ongoing Phase I study of NUC-7738 in patients with advanced solid tumors demonstrate that we can apply our ProTide technology platform to both existing as well as novel nucleoside analogs. We remain dedicated to our mission of developing more effective and safer medicines for patients with cancer."

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including NUC-3373, NUC-7738 and Acelarin; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith

    Chief Executive Officer

    NuCana plc

    Tel: +44 131 357 1111

    Westwicke, an ICR Company

    Chris Brinzey

    Tel: +1 339-970-2843

    RooneyPartners

    Marion Janic

    Tel: +1 212-223-4017

    View Full Article Hide Full Article
  10. EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the closing of its previously announced underwritten public offering of 17,888,889 American Depositary Shares ("ADSs"), at a public offering price of $4.50 per ADS, which includes 2,333,333 additional ADSs issued upon the exercise in full of the underwriters' option to purchase additional ADSs. The aggregate gross proceeds to NuCana from the offering, before deducting underwriting discounts and commissions and estimated offering expenses were $80.5 million. All of the ADSs in the offering were sold by NuCana.

    Jefferies, Cowen, William…

    EDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the closing of its previously announced underwritten public offering of 17,888,889 American Depositary Shares ("ADSs"), at a public offering price of $4.50 per ADS, which includes 2,333,333 additional ADSs issued upon the exercise in full of the underwriters' option to purchase additional ADSs. The aggregate gross proceeds to NuCana from the offering, before deducting underwriting discounts and commissions and estimated offering expenses were $80.5 million. All of the ADSs in the offering were sold by NuCana.

    Jefferies, Cowen, William Blair, and Truist Securities acted as joint book-running managers for the offering.

    The securities were offered pursuant to a shelf registration statement on Form F-3 which has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on October 22, 2018. This offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available for free on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may also be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340 or by e-mail at , or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, email: , telephone: 1-833-297-2926, or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at , or Truist Securities, Inc., 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attention: Prospectus Department; email: . For the avoidance of doubt, such prospectus does not constitute a "prospectus" for the purposes of the Prospectus Regulation (as defined below) and has not been reviewed by any competent authority in any EEA member state or the United Kingdom.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

    For readers in the European Economic Area (EEA) and the United Kingdom

    In any EEA Member State and the United Kingdom (a "Relevant State"), this communication is only addressed to and directed at "qualified investors" in that Relevant State within the meaning of the Prospectus Regulation (Regulation (EU) 2017/1129) (the "Prospectus Regulation").

    Further notice for readers in the United Kingdom

    There will be no offer of ADSs to the public in the United Kingdom. This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 as amended ("FSMA")) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) ("Investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc.") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as "relevant persons"). The ADSs are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This communication does not contain an offer or constitute any part of an offer to the public within the meaning of ss. 85 and 102B of FSMA or otherwise.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, subsequent reports that the Company files with the SEC and the final prospectus supplement related to this offering. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:

    View Full Article Hide Full Article
  11. EDINBURGH, United Kingdom, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the pricing of an underwritten public offering of 15,555,556 American Depositary Shares ("ADSs") at a price to the public of $4.50 per ADS, for total gross proceeds of approximately $70.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. Each ADS represents one ordinary share of NuCana. In addition, NuCana has granted the underwriters a 30-day option to purchase up to 2,333,333 additional ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs in the…

    EDINBURGH, United Kingdom, Sept. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the pricing of an underwritten public offering of 15,555,556 American Depositary Shares ("ADSs") at a price to the public of $4.50 per ADS, for total gross proceeds of approximately $70.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. Each ADS represents one ordinary share of NuCana. In addition, NuCana has granted the underwriters a 30-day option to purchase up to 2,333,333 additional ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs in the offering will be sold by NuCana. The offering is expected to close on or about September 21, 2020, subject to the satisfaction of customary closing conditions.

    Jefferies, Cowen, William Blair, and Truist Securities are acting as joint book-running managers for the offering.

    The securities are being offered pursuant to a shelf registration statement on Form F-3 which has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on October 22, 2018. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on September 16, 2020 and is available on the SEC's website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus relating to this offering may also be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340 or by e-mail at , or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, email: , telephone: 1-833-297-2926, or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at , or Truist Securities, Inc., 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attention: Prospectus Department; email: . For the avoidance of doubt, such prospectus will not constitute a "prospectus" for the purposes of the Prospectus Regulation (as defined below) and will not have been reviewed by any competent authority in any EEA member state or the United Kingdom.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

    For readers in the European Economic Area (EEA) and the United Kingdom

    In any EEA Member State and the United Kingdom (a "Relevant State"), this communication is only addressed to and directed at "qualified investors" in that Relevant State within the meaning of the Prospectus Regulation (Regulation (EU) 2017/1129) (the "Prospectus Regulation").

    Further notice for readers in the United Kingdom

    There will be no offer of ADSs to the public in the United Kingdom. This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 as amended ("FSMA")) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) ("Investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc.") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as "relevant persons"). The ADSs are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This communication does not contain an offer or constitute any part of an offer to the public within the meaning of ss. 85 and 102B of FSMA or otherwise.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the completion and timing of the public offering and the anticipated total gross proceeds from the offering. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, subsequent reports that the Company files with the SEC and the final prospectus supplement related to this offering. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:

    View Full Article Hide Full Article
  12. EDINBURGH, United Kingdom, Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it has commenced an underwritten public offering of its American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of NuCana. In addition, NuCana expects to grant the underwriters a 30-day option to purchase up to an additional 15% of its ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by NuCana. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the…

    EDINBURGH, United Kingdom, Sept. 16, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that it has commenced an underwritten public offering of its American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of NuCana. In addition, NuCana expects to grant the underwriters a 30-day option to purchase up to an additional 15% of its ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by NuCana. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

    Jefferies, Cowen, William Blair, and Truist Securities are acting as joint book-running managers for the offering.

    The securities are being offered pursuant to a registration statement on Form F-3 which has been filed with the U.S. Securities and Exchange Commission (the "SEC") and was declared effective on October 22, 2018. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. Copies of the preliminary prospectus supplement related to this offering and the accompanying prospectus will be filed with the SEC and will be available on the SEC's website at www.sec.gov and may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340 or by e-mail at , or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, email: , telephone: 1-833-297-2926, or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at , or Truist Securities, Inc., 3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attention: Prospectus Department; email: .  For the avoidance of doubt, such prospectus will not constitute a "prospectus" for the purposes of the Prospectus Regulation (as defined below) and will not have been reviewed by any competent authority in any EEA member state or the United Kingdom.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

    For readers in the European Economic Area (EEA) and the United Kingdom

    In any EEA Member State and the United Kingdom (a "Relevant State"), this communication is only addressed to and directed at "qualified investors" in that Relevant State within the meaning of the Prospectus Regulation (Regulation (EU) 2017/1129).

    Further notice for readers in the United Kingdom

    There will be no offer of ADSs to the public in the United Kingdom. This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 as amended ("FSMA")) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) ("Investment professionals") of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) ("High net worth companies, unincorporated associations etc.") of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as "relevant persons"). The ADSs are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This communication does not contain an offer or constitute any part of an offer to the public within the meaning of ss. 85 and 102B of FSMA or otherwise.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the anticipated final terms including the amount of ADSs the Company intends to sell, timing and completion of the proposed offering. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, subsequent reports that the Company files with the SEC and the preliminary prospectus supplement related to this offering. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:

    View Full Article Hide Full Article
  13. EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of June 30, 2020, NuCana had cash and cash equivalents of £47.8 million compared to £47.6 million as of March 31, 2020 and £52.0 million as of December 31, 2019. NuCana continues to advance its various clinical programs and reported a net loss of £6.1 million for the quarter ended June 30, 2020, as compared to £4.5 million for the quarter ended June 30, 2019. Basic and diluted loss per share was £0.19 for the quarter as compared to £0.14 per share for the prior-year quarter.

    "We had…

    EDINBURGH, United Kingdom, Aug. 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the second quarter ended June 30, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of June 30, 2020, NuCana had cash and cash equivalents of £47.8 million compared to £47.6 million as of March 31, 2020 and £52.0 million as of December 31, 2019. NuCana continues to advance its various clinical programs and reported a net loss of £6.1 million for the quarter ended June 30, 2020, as compared to £4.5 million for the quarter ended June 30, 2019. Basic and diluted loss per share was £0.19 for the quarter as compared to £0.14 per share for the prior-year quarter.

    "We had a very productive second quarter despite the COVID-19 pandemic. While we placed a brief pause on the recruitment of new patients in April, we have since lifted that pause and our operations have experienced minimal disruption to date", said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "We are driving recruitment in the ongoing global Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer. We are also making good progress in the Phase Ib combination and Phase I monotherapy studies of NUC-3373 as well as the Phase I study of NUC-7738."

    Mr. Griffith continued: "We are also excited to have three posters accepted for presentation at the ESMO Virtual Congress 2020 to be held September 19-21, 2020. We look forward to presenting additional interim clinical data from the ongoing Phase Ib study of NUC-3373 in combination with other agents typically combined with 5-FU in patients with advanced colorectal cancer (NuTide:302). Additionally, we will present the first-ever clinical data from the ongoing Phase I study of NUC-7738 in patients with advanced solid tumors (NuTide:701). Finally, we will present a poster related to the ongoing NuTide:121 study of Acelarin plus cisplatin in patients with advanced biliary tract cancer."

    The poster titles are as follows:

    • Poster 464P - Pharmacokinetic analysis of NUC-3373 with and without leucovorin in patients with previously treated metastatic colorectal cancer (NuTide:302 study)

       
    • Poster 600TiP - A first-in-human study of, NUC-7738, a 3'-dA phosphoramidate, in patients with advanced solid tumors (NuTide:701)

       
    • Poster 80TiP - Global Phase 3 study of NUC-1031 plus cisplatin vs gemcitabine plus cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)

    Mr. Griffith said: "We were also pleased to have presented data at the American Association for Cancer Research in June that suggested an additional immunomodulatory mode of action for Acelarin and NUC-3373.  These data showed our ProTides' potential to alter tumor biology and enhance the activity of immune checkpoint inhibitors. They also revealed new and exciting modes of action and help explain why our ProTides appear to be such potent anti-cancer agents."

    Mr. Griffith concluded: "As we continue to advance our novel ProTide pipeline, we remain fortunate to be in a strong financial position with our cash runway still expected to extend at least into the fourth quarter of 2021.  We remain focused on advancing our novel ProTide pipeline to develop more effective and safer medicines for patients with cancer."

    Anticipated 2020 Milestones

    • Acelarin is a ProTide transformation of gemcitabine. In 2020, NuCana expects to:

       
      • Drive enrollment in the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.

         
    • NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-FU. In 2020, NuCana expects to:

       
      • Report data from the ongoing Phase Ib study (NuTide:302) of NUC-3373 in patients with advanced colorectal cancer and establish the recommended Phase II dose of NUC-3373 in combination with other agents with which 5-FU is typically combined, such as leucovorin, oxaliplatin and irinotecan.
      • Contingent on regulatory guidance and other factors, initiate a Phase II/III study of NUC-3373 in combination with other agents for patients with colorectal cancer.
      • Report data from the ongoing Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors.

         
    • NUC-7738 is a ProTide transformation of a novel nucleoside analog, 3'-deoxyadenosine. In 2020, NuCana expects to:

       
      • Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana's robust pipeline includes three ProTides in clinical development. Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the amount and sufficiency of the Company's current cash and cash equivalents to fund its planned operations at least into the fourth quarter of 2021; the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.





    Unaudited Condensed Consolidated Statements of Operations

      For the three months ended

    June 30,
     For the six months ended

    June 30,
      2020 2019  2020 2019 
      (in thousands, except per share data)
      £ £  £ £ 
    Research and development expenses (5,863)(5,356) (11,801)(9,706)
    Administrative expenses (1,629)(1,462) (3,238)(2,808)
    Net foreign exchange gains (losses) 84 943  2,211 (37)
    Operating loss (7,408)(5,875) (12,828)(12,551)
    Finance income 64 297  208 616 
    Loss before tax  (7,344)(5,578) (12,620)(11,935)
    Income tax credit 1,283 1,108  2,593 2,108 
    Loss for the period (6,061)(4,470) (10,027)(9,827)
           
           
    Basic and diluted loss per share (0.19)(0.14) (0.31)(0.30)
           
           





    Unaudited Condensed Consolidated Statements of Financial Position

      June 30,

     2020
     December 31,

    2019
     
      (in thousands)
      £ £ 
    Assets   
    Non-current assets   
    Intangible assets 4,534 3,960 
    Property, plant and equipment 917 1,109 
    Deferred tax asset 40 46 
      5,491 5,115  
    Current assets   
    Prepayments, accrued income and other receivables 3,877 4,710 
    Current income tax receivable 6,932 8,481 
    Cash and cash equivalents 47,800 51,962 
      58,609 65,153  
    Total assets 64,100 70,268 
    Equity and liabilities   
    Capital and reserves   
    Share capital and share premium 82,783 80,840 
    Other reserves 64,360 62,737 
    Accumulated deficit (90,014)(80,055)
    Total equity attributable to equity holders of the Company 57,129 63,522 
        
    Non-current liabilities   
    Provisions 26 26 
    Lease liabilities 429 538 
      455 564 
        
    Current liabilities   
    Trade payables 1,928 2,412 
    Payroll taxes and social security 151 160 
    Lease liabilities 246 268 
    Accrued expenditure 4,191 3,342 
      6,516 6,182 
        
    Total liabilities 6,971 6,746 
        
    Total equity and liabilities 64,100 70,268 
          
          





    Unaudited Condensed Consolidated Statements of Cash Flows

     For the six months ended June 30,

     
     2020 2019 
     (in thousands)
     £ £ 
    Cash flows from operating activities  
    Loss for the period(10,027)(9,827)
    Adjustments for:  
    Income tax credit(2,593)(2,108)
    Amortization and depreciation440 336 
    Finance income(208)(616)
    Interest expense on lease liabilities14 - 
    Share-based payments1,669 1,166 
    Net foreign exchange (gains) losses(2,252)22 
     (12,957)(11,027)
    Movements in working capital:  
    Decrease (increase) in prepayments, accrued income and other receivables802 (1,518)
    Decrease in trade payables(484)(164)
    Increase in payroll taxes, social security and accrued expenditure840 1,063 
    Movements in working capital1,158 (619)
    Cash used in operations(11,799)(11,646)
    Net income tax received4,152 11 
    Net cash used in operating activities(7,647)(11,635)
    Cash flows from investing activities  
    Interest received279 622 
    Payments for property, plant and equipment(14)(21)
    Payments for intangible assets(804)(734)
    Net cash used in investing activities(539)(133)
    Cash flows from financing activities  
    Payments of lease liabilities(148)(95)
    Proceeds from issue of share capital – exercise of share options15 86 
    Proceeds from issue of share capital2,033 - 
    Share issue expenses(105)- 
    Net cash from (used in) financing activities 1,795 (9)
    Net decrease in cash and cash equivalents(6,391)(11,777)
    Cash and cash equivalents at beginning of period51,962 76,972 
    Effect of exchange rate changes on cash and cash equivalents2,229 (21)
    Cash and cash equivalents at end of period47,800 65,174 
         
         



    For more information, please contact:

    NuCana plc

    Hugh S. Griffith

    Chief Executive Officer

    T: +44 131 357 1111

    E:

    Westwicke, an ICR Company

    Chris Brinzey

    T: +1 339-970-2843

    E:

    RooneyPartners

    Marion Janic

    T: +1 212-223-4017

    E:

    View Full Article Hide Full Article
  14. Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic

    Numerous Clinical Data Announcements Expected in 2020

    Cash and Cash Equivalents Expected to Fund Operations At Least into the Fourth Quarter of 2021

    EDINBURGH, United Kingdom, May 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the first quarter ended March 31, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of March 31, 2020, NuCana had cash and cash equivalents of £47.6 million compared to £52.0 million as of December 31, 2019. NuCana continues to advance its various clinical programs and reported a net loss of £4.0 million for the quarter…

    Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic

    Numerous Clinical Data Announcements Expected in 2020

    Cash and Cash Equivalents Expected to Fund Operations At Least into the Fourth Quarter of 2021

    EDINBURGH, United Kingdom, May 19, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the first quarter ended March 31, 2020 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of March 31, 2020, NuCana had cash and cash equivalents of £47.6 million compared to £52.0 million as of December 31, 2019. NuCana continues to advance its various clinical programs and reported a net loss of £4.0 million for the quarter ended March 31, 2020, as compared to £5.4 million for the quarter ended March 31, 2019. Basic and diluted loss per share was £0.12 for the quarter as compared to £0.17 per share for quarter ended March 31, 2019.

    "At NuCana, we remain focused on advancing our novel ProTide pipeline to develop more effective and safer medicines for patients with cancer" said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "The COVID-19 pandemic has had a dramatic impact on the global healthcare delivery system and caused us to pause enrollment of new patients in our ongoing clinical studies in early April. However, we are pleased to have now re-started new patient enrollment in our clinical studies, including NuTide:121, our Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer, and NuTide:302, our Phase Ib study of NUC-3373 in patients with colorectal cancer. We will resume enrollment of new patients at all of our clinical sites as quickly as possible. We are also fortunate to be in a strong financial position during this unprecedented time. As a result of having undertaken several cost-saving and cost-deferral initiatives, we believe our cash runway now extends at least into the fourth quarter of 2021, as compared to our previous guidance of into the second half of 2021."

    Mr. Griffith continued: "Looking at progress in the quarter, we announced preliminary data from the Phase II study of single-agent Acelarin (NUC-1031) in patients with platinum-resistant ovarian cancer that demonstrated a favorable disease control rate and Acelarin's ability to achieve confirmed complete and partial responses in a very heavily pre-treated patient population. While we had previously announced that we are not advancing Acelarin as a single agent in this setting due to changes in the treatment and regulatory landscapes, we were pleased with the preliminary results of this study and believe that the data highlights the potential of our ProTide platform. We are also rapidly advancing our two other ProTides in the clinic. For NUC-3373, our ProTide transformation of 5-FU, we look forward to reporting additional data from the ongoing Phase Ib study in patients with advanced colorectal cancer and the Phase I dose-escalation study in patients with advanced solid tumors. For our third ProTide, NUC-7738, a transformation of a novel nucleoside analog, 3'-deoxyadenosine, we expect to announce the first clinical data from the ongoing Phase I study in patients with advanced solid tumors later this year."

    Mr. Griffith concluded: "COVID-19 has had a dramatic and profound impact on healthcare systems worldwide. Despite these challenges, we are greatly encouraged by how our employees, investigators and other key stakeholders have adapted to this situation, responded positively and continued to drive our development programs forward."

    Anticipated 2020 Milestones

    • Acelarin is NuCana's ProTide transformation of gemcitabine. In 2020, NuCana expects to:
       
      • Drive enrollment in the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.
         
    • NUC-3373 is NuCana's second ProTide in clinical development, a transformation of the active anti-cancer metabolite of 5-FU. In 2020, NuCana expects to:
       
      • Report data from the ongoing Phase Ib study (NuTide:302) of NUC-3373 in patients with advanced colorectal cancer and establish the recommended Phase II dose of NUC-3373 in combination with other agents with which 5-FU is typically combined, including leucovorin, oxaliplatin and irinotecan.
      • Contingent on regulatory guidance and other factors, initiate a Phase II/III study of NUC-3373 in combination with other agents for patients with colorectal cancer.
      • Report data from the ongoing Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors.
         
    • NUC-7738 is NuCana's ProTide transformation of a novel nucleoside analog, 3'-deoxyadenosine. In 2020, NuCana expects to:
       
      • Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with previously treated metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the amount and sufficiency of the Company's current cash and cash equivalents to fund its planned operations at least into the fourth quarter of 2021; the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.


    Unaudited Condensed Consolidated Statements of Operations

        For the Three Months Ended
    March 31,
        2020 2019
        (in thousands, except per share data)
        £ £
    Research and development expenses   (5,938)   (4,350)  
    Administrative expenses   (1,609)   (1,346)  
    Net foreign exchange gains (losses)   2,127   (979)  
    Operating loss    (5,420)   (6,675)  
    Finance income   144   318  
    Loss before tax   (5,276)   (6,357)  
    Income tax credit   1,310   1,000  
    Loss for the period   (3,966)   (5,357)  
    Basic and diluted loss per share   (0.12)   (0.17)  


    Unaudited Condensed Consolidated Statements of Financial Position

        March 31, 2020 December 31, 2019
        (in thousands)
        £ £
    Assets      
    Non-current assets      
    Intangible assets   4,246   3,960  
    Property, plant and equipment   1,018   1,109  
    Deferred tax asset   44   46  
        5,308   5,115  
               
    Current assets      
    Prepayments, accrued income and other receivables   4,290   4,710  
    Current income tax receivable   9,797   8,481  
    Cash and cash equivalents   47,600   51,962  
        61,687   65,153  
    Total assets   66,995   70,268  
               
    Equity and liabilities      
    Capital and reserves      
    Share capital and share premium   80,840   80,840  
    Other reserves   63,614   62,737  
    Accumulated deficit   (84,021)   (80,055)  
    Total equity attributable to equity holders of the Company   60,433   63,522  
               
    Non-current liabilities      
    Provisions   26   26  
    Lease liabilities   485   538  
        511   564  
               
           
    Current liabilities      
    Trade payables   2,456   2,412  
    Payroll taxes and social security   148   160  
    Lease liabilities   258   268  
    Accrued expenditure   3,189   3,342  
        6,051   6,182  
    Total liabilities   6,562   6,746  
    Total equity and liabilities    66,995   70,268  


    Unaudited Condensed Consolidated Statements of Cash Flows

        For the Three Months Ended
    March 31,
        2020 2019
        (in thousands)
        £ £
    Cash flows from operating activities      
    Loss for the period   (3,966)   (5,357)  
    Adjustments for:      
    Income tax credit   (1,310)   (1,000)  
    Amortization and depreciation   217   161  
    Finance income   (144)   (318)  
    Share-based payments   856   384  
    Net foreign exchange (gains) losses   (2,164)   984  
        (6,511)   (5,146)  
    Movements in working capital:      
    Decrease (increase) in prepayments, accrued income and other receivables   423   (402)  
    Increase (decrease) in trade payables   44   (197)  
    Decrease in payroll taxes, social security and accrued expenditure   (165)   (347)  
    Movements in working capital   302   (946)  
    Cash used in operations   (6,209)   (6,092)  
    Net income tax received   -   -  
    Net cash used in operating activities   (6,209)   (6,092)  
               
    Cash flows from investing activities      
    Interest received   187   311  
    Payments for property, plant and equipment   (10)   (18)  
    Payments for intangible assets   (398)   (280)  
    Net cash (used in) from investing activities   (221)   13  
               
    Cash flows from financing activities      
    Payments for lease liabilities   (73)   (40)  
    Proceeds from issue of share capital   -   34  
    Net cash used in financing activities   (73)   (6)  
    Net decrease in cash and cash equivalents   (6,503)   (6,085)  
    Cash and cash equivalents at beginning of period   51,962   76,972  
    Effect of exchange rate changes on cash and cash equivalents    2,141   (979)  
    Cash and cash equivalents at end of period    47,600   69,908  


    For more information, please contact:

    NuCana plc
    Hugh S. Griffith
    Chief Executive Officer
    +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    +1 339-970-2843

    RooneyPartners
    Marion Janic
    +1 212-223-4017

     

    View Full Article Hide Full Article
  15. EDINBURGH, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic. NuCana previously announced the re-opening of its global Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer (NuTide:121) on May 5, 2020. NuCana has now also re-opened the Phase I and Phase Ib clinical studies of NUC-3373 and the Phase I clinical study of NUC-7738.

    "All of our clinical studies have now re-opened to new patient enrollment and we are pleased to be treating once again new patients who may benefit from our ProTides," said Hugh S. Griffith, NuCana's Founder and Chief…

    EDINBURGH, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic. NuCana previously announced the re-opening of its global Phase III study of Acelarin plus cisplatin in patients with biliary tract cancer (NuTide:121) on May 5, 2020. NuCana has now also re-opened the Phase I and Phase Ib clinical studies of NUC-3373 and the Phase I clinical study of NUC-7738.

    "All of our clinical studies have now re-opened to new patient enrollment and we are pleased to be treating once again new patients who may benefit from our ProTides," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "The COVID-19 pandemic has had a dramatic impact on the global healthcare delivery system and advancing clinical studies of potential new treatments for cancer patients is of critical importance to NuCana."

    The following clinical studies have re-opened to new-patient enrollment:

    • NuTide:121, the Phase III study of Acelarin (NUC-1031) plus cisplatin in patients with biliary tract cancer. The re-opening of NuTide:121 has begun in certain geographies including Australia, Canada, South Korea, Taiwan, Ukraine and the United Kingdom.
       
    • NuTide:302, the Phase Ib study of NUC-3373 in combination with other agents typically combined with 5-fluorouacil (5-FU) in patients with advanced colorectal cancer. The re-opening of NuTide:302 has begun in the United Kingdom.
       
    • NuTide:301, the Phase I clinical study of NUC-3373 in patients with advanced solid tumors.
       
    • NuTide:701, the Phase I clinical study of NUC-7738 in patients with advanced solid tumors.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with previously treated metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc
    Hugh S. Griffith
    Chief Executive Officer
    +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    +1 339-970-2843

    RooneyPartners
    Marion Janic
    +1 212-223-4017

    View Full Article Hide Full Article
  16. Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells

    Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells

    NUC-3373 Induces Endoplasmic Reticulum Stress and Release of DAMPs in Colorectal Cancer Cells

    EDINBURGH, United Kingdom, May 15, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) today announced that two abstracts describing non-clinical studies related to the mechanisms of action of its proprietary ProTides, Acelarin (NUC-1031) and NUC-3373, were selected for poster presentations at the AACR Annual Meeting 2020 on June 22-24, 2020.

    In prior non-clinical studies, Acelarin has shown an ability to cause cancer-cell death via DNA damage.   These new…

    Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells

    Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells

    NUC-3373 Induces Endoplasmic Reticulum Stress and Release of DAMPs in Colorectal Cancer Cells

    EDINBURGH, United Kingdom, May 15, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) today announced that two abstracts describing non-clinical studies related to the mechanisms of action of its proprietary ProTides, Acelarin (NUC-1031) and NUC-3373, were selected for poster presentations at the AACR Annual Meeting 2020 on June 22-24, 2020.

    In prior non-clinical studies, Acelarin has shown an ability to cause cancer-cell death via DNA damage.   These new in vitro data presented at AACR suggest that Acelarin may also have a potential immunomodulatory role. Acelarin was found to cause the release of Damage Associated Molecular Patterns, or DAMPs, and increase the expression of PD-L1 on cancer cells. The findings indicate that Acelarin produces changes in the cancer cells and the tumor microenvironment that could alter the recognition by the immune system, thus potentially making Acelarin an attractive combination partner for immune checkpoint inhibitors.

    In the second AACR abstract, an additional novel mode of action was identified for NUC-3373, NuCana's ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU), a very widely used anti-cancer drug.  NUC-3373 was found to be a potent inhibitor of thymidylate synthase, which results in DNA damage of cancer cells.  The recent in vitro studies have shown NUC-3373 is able to not only damage DNA, but also induce endoplasmic reticulum stress, and the subsequent release of DAMPs.  Thus, in addition to being effective DNA damaging agents in cancer cells, these data suggest that both NUC-3373 and Acelarin may have the potential to alter tumor biology and enhance the activity of immune checkpoint inhibitors.

    Hugh S. Griffith, NuCana's Chief Executive Officer, said: "These findings reveal new and exciting modes of action of our ProTides and help to explain why they appear to be such potent anti-cancer agents."

    Acelarin is currently being evaluated in a global Phase III study in combination with cisplatin as a first-line treatment for patients with advanced biliary tract cancer. NUC-3373 is in a Phase Ib clinical study in patients with advanced colorectal cancer in combination with other agents with which 5-FU is typically combined and a Phase I clinical study in patients with advanced solid tumors.  NuCana's third ProTide, NUC-7738, a transformation of a novel nucleoside analog, 3'-deoxyadenosine, is in a Phase I study in patients with advanced solid tumors.

    Details of NuCana's e-poster presentations on June 22-24, 2020: AACR Virtual Annual Meeting II are as follows:

    Abstract Title:  NUC-1031 causes release of DAMPs and upregulates PD-L1 expression in lung cancer cells
    Poster Number: 1840
    Poster Session Title:  Mechanisms of Drug Action 2

    Abstract Title:  NUC-3373 induces ER stress and the release of damage-associated molecular patterns in colorectal cancer cells
    Poster Number: 1848
    Poster Session Title: Mechanisms of Drug Action 2

    Abstracts and full session details can be found at www.aacr.org

    About NuCana plc
    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with previously treated metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements
    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned, ongoing and completed non-clinical and clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned, ongoing and completed non-clinical and clinical studies; the impact of COVID-19 on its non-clinical studies, clinical studies, business, financial condition and results of operations; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:
    NuCana plc
    Hugh S. Griffith
    Chief Executive Officer
    +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    +1 339-970-2843

    RooneyPartners
    Marion Janic
    +1 212-223-4017

    View Full Article Hide Full Article
  17. EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin (NUC-1031) plus cisplatin in patients with biliary tract cancer. The re-opening of NuTide:121 has begun in certain geographies, including Australia, Canada, South Korea, Taiwan, Ukraine and the United Kingdom.  NuCana will work closely with the clinicians involved in NuTide:121 to re-open all of the clinical sites to new patient enrollment as soon as practicable.

    "We will continue to monitor the impact of the COVID-19 pandemic, but re-opening this study is important for patients with biliary tract cancer who need treatment," said Hugh S. Griffith, NuCana's…

    EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin (NUC-1031) plus cisplatin in patients with biliary tract cancer. The re-opening of NuTide:121 has begun in certain geographies, including Australia, Canada, South Korea, Taiwan, Ukraine and the United Kingdom.  NuCana will work closely with the clinicians involved in NuTide:121 to re-open all of the clinical sites to new patient enrollment as soon as practicable.

    "We will continue to monitor the impact of the COVID-19 pandemic, but re-opening this study is important for patients with biliary tract cancer who need treatment," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer.  Mr. Griffith added "The COVID-19 pandemic has had a dramatic impact on the global healthcare delivery system and on cancer patient care, and it is vital that the development of new cancer treatments, such as Acelarin, is resumed as quickly as possible."

    NuTide:121 is a global, multi-center, randomized Phase III study of Acelarin, NuCana's ProTide transformation of gemcitabine, that will enroll up to 828 patients in approximately 120 sites across North America, Europe, Asia and Australia. Patients are being randomized 1:1 and treated with either a combination of Acelarin (725 mg/m2) plus cisplatin (25 mg/m2) or the current standard of care regimen, gemcitabine (1,000 mg/m2) plus cisplatin (25 mg/m2).

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with previously treated metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc
    Hugh S. Griffith
    Chief Executive Officer
    +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    +1 339-970-2843

    RooneyPartners
    Marion Janic
    +1 212-223-4017

    View Full Article Hide Full Article
  18. EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today an update on the status of its ongoing clinical studies.  In order to help to protect the health of patients and investigators at its clinical study sites, the enrollment of new patients in its ongoing clinical studies has been temporarily paused.  Patients who are currently enrolled in NuCana's ongoing studies are continuing to receive treatment. 

    "This pandemic has dramatically impacted the global healthcare delivery system and altered the landscape not only for NuCana, but also for the wider biotech industry and society as a whole," said Hugh…

    EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today an update on the status of its ongoing clinical studies.  In order to help to protect the health of patients and investigators at its clinical study sites, the enrollment of new patients in its ongoing clinical studies has been temporarily paused.  Patients who are currently enrolled in NuCana's ongoing studies are continuing to receive treatment. 

    "This pandemic has dramatically impacted the global healthcare delivery system and altered the landscape not only for NuCana, but also for the wider biotech industry and society as a whole," said Hugh S. Griffith, NuCana's CEO. "This temporary pause in enrollment of new patients will help to ease the burden on our study sites and enable healthcare professionals to focus their efforts on caring for patients with COVID-19. We have also adapted ongoing studies to reduce the risk of exposure to the coronavirus by minimizing the time patients need to be in the hospital for study visits."

    While NuCana continues to evaluate the impact of COVID-19 on its operations, the company believes that this pandemic will inevitably cause some delays to the timing of initiation and completion of its clinical studies. However, the precise timing of delays and overall impact is currently unknown and NuCana is continuing to monitor the COVID-19 pandemic as it rapidly evolves.

    Mr. Griffith concluded: "We remain committed to resuming the enrollment of new patients as quickly as possible. I am confident that NuCana has the resources and resolve to navigate this pandemic."  

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with previously treated metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2019 filed with the Securities and Exchange Commission ("SEC") on March 10, 2020, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    NuCana plc
    Hugh S. Griffith
    Chief Executive Officer
    +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    +1 339-970-2843

    RooneyPartners
    Marion Janic
    +1 212-223-4017

    View Full Article Hide Full Article
  19. First Patients Dosed in Global Phase III Biliary Tract Cancer Study (NuTide:121) 
    with Potential for Accelerated Approval Filing

    Numerous Clinical Data Announcements Expected in 2020

    Cash and Cash Equivalents to Fund Operations into the Second Half of 2021

    EDINBURGH, United Kingdom, March 10, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the fourth quarter and year ended December 31, 2019 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of December 31, 2019, NuCana had cash and cash equivalents of £52.0 million compared to £58.1 million as of September 30, 2019 and £77.0 million as of December 31, 2018. NuCana continues to advance its various clinical programs…

    First Patients Dosed in Global Phase III Biliary Tract Cancer Study (NuTide:121) 
    with Potential for Accelerated Approval Filing

    Numerous Clinical Data Announcements Expected in 2020

    Cash and Cash Equivalents to Fund Operations into the Second Half of 2021

    EDINBURGH, United Kingdom, March 10, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the fourth quarter and year ended December 31, 2019 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

    As of December 31, 2019, NuCana had cash and cash equivalents of £52.0 million compared to £58.1 million as of September 30, 2019 and £77.0 million as of December 31, 2018. NuCana continues to advance its various clinical programs and reported a net loss of £7.7 million for the quarter ended December 31, 2019, as compared to £3.6 million for the quarter ended December 31, 2018. Net loss for the year ended December 31, 2019 was £21.4 million, compared to a net loss of £13.8 million for the year ended December 31, 2018. Basic and diluted loss per share was £0.24 for the quarter and £0.66 for the year ended December 31, 2019, as compared to £0.11 per share for the comparable quarter and £0.43 for the year ended December 31, 2018.

    "It has been a productive year for NuCana in 2019 and we are making excellent progress advancing our pipeline of novel ProTides," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "The year was highlighted by the initiation of our global Phase III NuTide:121 study comparing Acelarin plus cisplatin to gemcitabine plus cisplatin as a first-line treatment for patients with advanced biliary tract cancer. NuTide:121 will enroll up to 828 patients and we have designed the study to potentially support both accelerated as well as full approval filings.  We look forward to expediting the recruitment of patients to this study."

    Mr. Griffith added: "We also continue to advance rapidly our other two ProTides in the clinic. For NUC-3373, our ProTide transformation of 5-FU, we recently presented clinical data from part one of NuTide:302, the Phase Ib study of NUC-3373 in combination with other agents typically combined with 5-FU in patients with advanced colorectal cancer. We look forward to presenting additional data in 2020 from this study, as well as from the monotherapy Phase I dose-escalation study of NUC-3373 in patients with advanced solid tumors (NuTide:301). Once we have established a dose and schedule for NUC-3373 in combination with other agents, we expect to initiate a registrational program of NUC-3373 in patients with colorectal cancer in 2020. We believe NUC-3373 has significant commercial potential as approximately 500,000 patients in North America alone are estimated to receive 5-FU each year."

    "For our third ProTide in the clinic, NUC-7738, a transformation of a novel nucleoside analog, 3'-deoxyadenosine, we announced in October non-clinical data detailing multiple potential anti-cancer modes of action resulting in cancer cell death. We look forward to announcing clinical data from the ongoing Phase I study of NUC-7738 in patients with advanced solid tumors (NuTide:701) in 2020."

    NuCana believes its current cash and cash equivalents will be sufficient to fund its planned operations into the second half of 2021. In addition to continuing or completing the ongoing clinical studies, NuCana expects its current cash and cash equivalents will enable the following:

    • Continuing to run the Phase III study of Acelarin in combination with cisplatin in patients with biliary tract cancer;
    • Initiating a Phase II/III study of NUC-3373 in combination with other agents for patients with colorectal cancer.

    Mr. Griffith concluded: "Overall we are pleased with our progress these past twelve months and feel we are positioned well as we enter 2020.  We have continued to validate our ProTide technology's ability to transform some of the most widely prescribed chemotherapy agents into what we believe will be more efficacious and safer treatments. With multiple milestones expected across our pipeline, we anticipate a busy and productive 2020 for NuCana."

    Anticipated Milestones

    • Acelarin is NuCana's ProTide transformation of gemcitabine. In 2020, NuCana expects to:
       
      • Drive enrollment in the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.
      • Report data from the Phase Ib study (ABC-08) of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.
         
    • NUC-3373 is NuCana's second ProTide in clinical development, a transformation of the active anti-cancer metabolite of 5-FU. In 2020, NuCana expects to:


      • Report data from the ongoing Phase Ib study (NuTide:302) of NUC-3373 in patients with advanced colorectal cancer and establish the recommended Phase II dose of NUC-3373 in combination with other agents with which 5-FU is typically combined, including leucovorin, oxaliplatin and irinotecan.
      • Contingent on regulatory guidance and other factors, initiate a Phase II/III study of NUC-3373 in combination with other agents for patients with colorectal cancer.
      • Report data from the ongoing Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors.
         
    • NUC-7738 is NuCana's ProTide transformation of a novel nucleoside analog, 3'-deoxyadenosine. In 2020, NuCana expects to:
       
      • Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with previously treated metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the amount and sufficiency of the Company's current cash and cash equivalents to fund its planned operations into the second half of 2021; the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the effects of the COVID-19 outbreak on our business operations and development timelines and the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

       
       
    Condensed Consolidated Statements of Operations  
        For the three months ended  December 31,   For the year ended December 31,  
        2019   2018   2019   2018  
        (in thousands, except per share data)  
        (unaudited)    
        £   £   £   £  
                               
    Research and development expenses     (5,177 )   (4,650 )   (19,728 )   (16,846 )
    Administrative expenses     (1,722 )   (1,585 )   (5,953 )   (5,184 )
    Net foreign exchange (losses) gains     (2,210 )   1,137     (1,019 )   2,902  
    Operating loss     (9,109 )   (5,098 )   (26,700 )   (19,128 )
    Finance income     182     326     1,049     1,065  
    Loss before tax     (8,927 )   (4,772 )   (25,651 )   (18,063 )
    Income tax credit     1,219     1,160     4,239     4,223  
    Loss for the period     (7,708 )   (3,612 )   (21,412 )   (13,840 )
                               
                               
    Basic and diluted loss per share     (0.24 )   (0.11 )   (0.66 )   (0.43 )
                               
                               


    Condensed Consolidated Statements of Financial Position 
    at December 31,
        2019   2018  
        (in thousands)  
        £   £  
    Assets              
    Non-current assets              
    Intangible assets     3,960     3,122  
    Property, plant and equipment     1,109     427  
    Deferred tax asset     46     47  
          5,115     3,596  
                   
    Current assets              
    Prepayments, accrued income and other receivables     4,710     2,354  
    Current income tax receivable     8,481     4,263  
    Cash and cash equivalents     51,962     76,972  
          65,153     83,589  
                   
    Total assets     70,268     87,185  
                   
    Equity and liabilities              
    Capital and reserves              
    Share capital and share premium     80,840     80,715  
    Other reserves     62,737     59,692  
    Accumulated deficit     (80,055 )   (58,813 )
    Total equity attributable to equity holders of the Company     63,522     81,594  
                   
    Non-current liabilities              
    Provisions     26     26  
    Lease liabilities     538     -  
          564     26  
                   
    Current liabilities              
    Trade payables     2,412     2,455  
    Payroll taxes and social security     160     127  
    Accrued expenditure     3,342     2,983  
    Lease liabilities     268     -  
          6,182     5,565  
                   
    Total liabilities     6,746     5,591  
                   
    Total equity and liabilities     70,268     87,185  
                   
                   


    Condensed Consolidated Statements of Cash Flows
    for the year ended December 31,
      2019   2018  
      (in thousands)  
      £   £  
    Cash flows from operating activities          
    Loss for the year   (21,412 ) (13,840 )
    Adjustments for:          
    Income tax credit   (4,239 ) (4,223 )
    Amortization and depreciation   718   371  
    Finance income   (1,049 ) (1,065 )
    Share-based payments   3,226   1,795  
    Net foreign exchange losses (gains)   1,006   (2,959 )
        (21,750 ) (19,921 )
    Movements in working capital:          
    (Increase) decrease in prepayments,          
    accrued income and other receivables   (2,452 817  
    (Decrease) increase in trade payables   (43 1,335  
    Increase in payroll taxes, social security          
    and accrued expenditure   393   1,321  
    Movements in working capital   (2,102 3,473  
    Cash used in operations   (23,852 ) (16,448 )
    Net income tax received   19   4,224  
    Net cash used in operating activities   (23,833 ) (12,224 )
    Cash flows from investing activities          
    Interest received   1,116   973  
    Payments for property, plant and equipment   (46 ) (210 )
    Payments for intangible assets   (1,215 ) (1,414 )
    Net cash used in investing activities   (145 ) (651 )
    Cash flows from financing activities          
    Payments of lease liabilities   (197 ) -  
    Proceeds from lease incentives received   25   -  
    Proceeds from issue of share capital   125   207  
    Net cash (used in) from financing activities   (47 207  
    Net decrease in cash and cash equivalents   (24,025 ) (12,668 )
    Cash and cash equivalents at beginning of year   76,972   86,703  
    Effect of exchange rate changes on cash and cash equivalents    (985 2,937  
    Cash and cash equivalents at end of year   51,962   76,972  
               
               

    For more information, please contact:

    NuCana plc
    Hugh S. Griffith
    Chief Executive Officer
    +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    +1 339-970-2843

    RooneyPartners
    Marion Janic
    +1 212-223-4017

     

    View Full Article Hide Full Article
  20. EDINBURGH, United Kingdom, March 04, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for orphan drug designation of Acelarin for the treatment of patients with biliary tract cancer. Acelarin, in combination with cisplatin, is currently being evaluated in a global Phase III study (NuTide:121) for the first-line treatment of patients with biliary tract cancer.

    "The receipt of a positive opinion for our orphan drug application in the European Union marks another important milestone in Acelarin's development," said Hugh S. Griffith, NuCana's Chief Executive Officer. "Acelarin in combination with cisplatin has achieved…

    EDINBURGH, United Kingdom, March 04, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for orphan drug designation of Acelarin for the treatment of patients with biliary tract cancer. Acelarin, in combination with cisplatin, is currently being evaluated in a global Phase III study (NuTide:121) for the first-line treatment of patients with biliary tract cancer.

    "The receipt of a positive opinion for our orphan drug application in the European Union marks another important milestone in Acelarin's development," said Hugh S. Griffith, NuCana's Chief Executive Officer. "Acelarin in combination with cisplatin has achieved an approximate doubling in response rates when compared to the historical results achieved with the standard of care, gemcitabine plus cisplatin. NuTide:121 has the potential to establish Acelarin plus cisplatin as the first approved medicines for the treatment of patients with biliary tract cancer."

    Orphan Drug Designation in the European Union (EU) is available to companies developing products for life-threatening or chronically debilitating conditions that affect fewer than five in 10,000 people in the region. This designation creates regulatory and financial incentives for NuCana, including reduced fees from the EMA during the development phase and a 10-year market exclusivity period in the EU following marketing authorization.

    NuCana previously received Orphan Drug Designation for Acelarin from the FDA's Office of Orphan Products for the treatment of patients with biliary tract cancer.

    About the NuTide:121 Study

    NuTide:121 is a global, multi-center, randomized Phase III study that is enrolling up to 828 patients in approximately 120 sites across North America, Europe, Asia and Australia. Patients are being randomized 1:1 and treated with either a combination of Acelarin (725 mg/m2) plus cisplatin (25 mg/m2) or the current standard of care regimen, gemcitabine (1,000 mg/m2) plus cisplatin (25 mg/m2).

    The primary objectives of NuTide:121 are Overall Survival (OS) and Objective Response Rate (ORR). Three interim analyses, including two designed to support accelerated approval, are planned as part of the Phase III study protocol, in addition to the final analysis. Based on discussions with the FDA and subject to any further regulatory guidance, the Company believes that a statistically significant improvement in ORR at either of the first two interim analyses, supported by positive trends in other endpoints, could potentially allow for an accelerated approval of a new drug application (NDA) for Acelarin.  Accelerated approval requires a confirmatory clinical study to verify the drug's clinical benefit.  If accelerated approval were to occur, NuTide:121 would continue and the Company anticipates that data from subsequent analyses could provide the confirmatory data to support full (regular) approval.

    More information about this study may be found here.

    About Biliary Tract Cancer

    Biliary tract cancer, including cholangiocarcinoma, gallbladder and ampullary carcinoma, is cancer originating in the bile duct, a vessel that transports bile from the liver to the gallbladder and small intestine. Approximately 178,000 new cases of biliary tract cancer are diagnosed each year worldwide, with more than 18,000 of those diagnoses in the United States.  There are currently no agents approved for the treatment of biliary tract cancer; however, the worldwide standard of care in biliary tract cancer patients with locally advanced or metastatic disease is the combination of gemcitabine and cisplatin. Patients receiving this regimen have a median overall survival of 11.7 months.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with previously treated metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith
    Chief Executive Officer
    NuCana plc
    Tel: +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    Tel: +1 339-970-2843

    RooneyPartners
    Marion Janic
    Tel: +1 212-223-4017

    View Full Article Hide Full Article
  21. EDINBURGH, United Kingdom, Feb. 25, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Cowen and Company 40th Annual Health Care Conference in Boston, MA.

    Event:  Cowen and Company 40th Annual Health Care Conference, Boston, MA
    Presentation Date: Tuesday, March 3, 2020
    Presentation Time: 11:20 AM ET

    The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients…

    EDINBURGH, United Kingdom, Feb. 25, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Cowen and Company 40th Annual Health Care Conference in Boston, MA.

    Event:  Cowen and Company 40th Annual Health Care Conference, Boston, MA
    Presentation Date: Tuesday, March 3, 2020
    Presentation Time: 11:20 AM ET

    The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with previously treated metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith
    Chief Executive Officer
    NuCana plc
    Tel: +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    Tel: +1 339-970-2843

    RooneyPartners
    Marion Janic
    Tel: +1 212-223-4017

    View Full Article Hide Full Article
  22. Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin

    NuTide:121 Trials-in-Progress Poster Presented at ASCO-GI

    SAN FRANCISCO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced that the first patients have been dosed in its Phase III study of Acelarin (NUC-1031) plus cisplatin for the first-line treatment of patients with biliary tract cancer and that the study design is being presented at the ASCO-GI Conference in San Francisco. The enrollment of patients in NuTide:121 follows U.S. Food and Drug Administration (FDA) clearance of the company's investigational new drug application (IND) for Acelarin.

    "We are pleased to have commenced dosing the first patients…

    Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin

    NuTide:121 Trials-in-Progress Poster Presented at ASCO-GI

    SAN FRANCISCO, Jan. 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced that the first patients have been dosed in its Phase III study of Acelarin (NUC-1031) plus cisplatin for the first-line treatment of patients with biliary tract cancer and that the study design is being presented at the ASCO-GI Conference in San Francisco. The enrollment of patients in NuTide:121 follows U.S. Food and Drug Administration (FDA) clearance of the company's investigational new drug application (IND) for Acelarin.

    "We are pleased to have commenced dosing the first patients in our Phase III NuTide:121 study," said Hugh Griffith, NuCana's Chief Executive Officer. "Acelarin in combination with cisplatin has been shown in early clinical studies to achieve higher response rates compared to the current standard of care in patients with advanced biliary tract cancer, a devastating disease for which there is a significant need for more effective medicines."

    NuTide:121 is a global, multi-center, randomized Phase III study that is enrolling up to 828 patients in approximately 120 sites across North America, Europe, Asia and Australia. Patients are being randomized 1:1 and treated with either a combination of Acelarin (725 mg/m2) plus cisplatin (25 mg/m2) or the current standard of care regimen, gemcitabine (1,000 mg/m2) plus cisplatin (25 mg/m2).

    NuCana also announced the presentation of a poster "NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)" at the ASCO-GI Conference being held in San Francisco, CA.  The poster details the study design of NuTide:121 and reviews the encouraging results previously reported in the Phase Ib ABC-08 Study.  The poster may be found here.

    The primary objectives of NuTide:121 are Overall Survival (OS) and Objective Response Rate (ORR). Three interim analyses, including two designed to support accelerated approval, are planned as part of the Phase III study protocol, in addition to the final analysis. Based on discussions with the FDA and subject to any further regulatory guidance, the Company believes that a statistically significant improvement in ORR at either of the first two interim analyses, supported by positive trends in other endpoints, could potentially allow for an accelerated approval of a new drug application (NDA) for Acelarin.  Accelerated approval requires a confirmatory clinical study to verify the drug's clinical benefit.  If accelerated approval were to occur, NuTide:121 would continue and the Company anticipates that data from subsequent analyses could provide the confirmatory data to support full (regular) approval.

    More information about this study may be found here.

    About Biliary Tract Cancer

    Biliary tract cancer, including cholangiocarcinoma, gallbladder and ampullary carcinoma, is cancer originating in the bile duct, a vessel that transports bile from the liver to the gallbladder and small intestine. Approximately 178,000 new cases of biliary tract cancer are diagnosed each year worldwide, with more than 18,000 of those diagnoses in the United States.  There are currently no agents approved for the treatment of biliary tract cancer; however, the worldwide standard of care in biliary tract cancer patients with locally advanced or metastatic disease is the combination of gemcitabine and cisplatin. Patients receiving this regimen have a median overall survival of 11.7 months.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with previously treated metastatic colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the NuTide:121 clinical study; the protocol, statistical analysis plan and expected interim and final analyses from the NuTide:121 study; the Company's expectations and plans with respect to the potential regulatory pathway for Acelarin, including any potential for accelerated approval; the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies;  and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith
    Chief Executive Officer
    NuCana plc
    Tel: +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    Tel: +1 339-970-2843

    RooneyPartners
    Marion Janic
    Tel: +1 212-223-4017

    View Full Article Hide Full Article
  23. EDINBURGH, United Kingdom, Nov. 26, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY on December 3rd and 4th, 2019.

    Event: Piper Jaffray 31st Annual Healthcare Conference
    Dates: Tuesday, December 3rd and Wednesday, December 4th, 2019

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of…

    EDINBURGH, United Kingdom, Nov. 26, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Piper Jaffray 31st Annual Healthcare Conference in New York, NY on December 3rd and 4th, 2019.

    Event: Piper Jaffray 31st Annual Healthcare Conference
    Dates: Tuesday, December 3rd and Wednesday, December 4th, 2019

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with advanced colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies;  and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith
    Chief Executive Officer
    NuCana plc
    Tel: +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    Tel: +1 339-970-2843

    RooneyPartners
    Marion Janic
    Tel: +1 212-223-4017

    View Full Article Hide Full Article
  24. EDINBURGH, United Kingdom, Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2019 London Healthcare Conference in London, UK.

    Event: Jefferies 2019 London Healthcare Conference
    Presentation Date: Wednesday, November 20, 2019
    Presentation Time: 10:40 AM GMT

    The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our…

    EDINBURGH, United Kingdom, Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies 2019 London Healthcare Conference in London, UK.

    Event: Jefferies 2019 London Healthcare Conference
    Presentation Date: Wednesday, November 20, 2019
    Presentation Time: 10:40 AM GMT

    The presentation will be webcast live and available for replay under "Events & Presentations" in the Investors section of the Company's website at www.nucana.com.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in three clinical studies, including a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with advanced colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine or cordycepin) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith
    Chief Executive Officer
    NuCana plc
    Tel: +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    Tel: +1 339-970-2843

    RooneyPartners
    Marion Janic
    Tel: +1 212-223-4017

    View Full Article Hide Full Article
  25. Opens Phase III Global Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing

    Focusing Resources on Key Value-Driving Programs of Biliary Tract Cancer and Colorectal Cancer

    Cash and Cash Equivalents to Fund Operations into the Second Half of 2021

    Numerous Clinical Data Announcements and Study Initiations Expected in 2020

    EDINBURGH, United Kingdom, Nov. 13, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the third quarter ended September 30, 2019 and provided an update on its extensive clinical program with its transformative ProTide™ therapeutics.

    As of September 30, 2019, NuCana had cash and cash equivalents of £58.1 million compared to £65.2 million as of June 30, 2019 and…

    Opens Phase III Global Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing

    Focusing Resources on Key Value-Driving Programs of Biliary Tract Cancer and Colorectal Cancer

    Cash and Cash Equivalents to Fund Operations into the Second Half of 2021

    Numerous Clinical Data Announcements and Study Initiations Expected in 2020

    EDINBURGH, United Kingdom, Nov. 13, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the third quarter ended September 30, 2019 and provided an update on its extensive clinical program with its transformative ProTide™ therapeutics.

    As of September 30, 2019, NuCana had cash and cash equivalents of £58.1 million compared to £65.2 million as of June 30, 2019 and £77.0 million as of December 31, 2018. NuCana continues to advance its various clinical programs and reported a net loss of £3.9 million for the quarter ended September 30, 2019, as compared to £2.5 million for the quarter ended September 30, 2018. Basic and diluted loss per share was £0.12 for the quarter ended September 30, 2019, as compared to £0.08 per share for the quarter ended September 30, 2018.

    "We are making excellent progress advancing our pipeline of novel ProTides," said Hugh S. Griffith, NuCana's Founder and Chief Executive Officer. "We recently announced that we have received FDA clearance of our IND and have commenced patient enrollment in NuTide:121, our global Phase III study comparing Acelarin plus cisplatin to gemcitabine plus cisplatin in patients with advanced biliary tract cancer.  We are excited that NuTide:121 has the potential to support both accelerated as well as full approval filings and we look forward to expediting the recruitment of patients to this study."  NuTide:121 will enroll up to 828 patients in approximately 120 sites across North America, Europe, Asia and Australia.  The primary objectives are Overall Survival (OS) and Objective Response Rate (ORR). Three interim analyses, including two designed to support accelerated approval, are planned as part of the Phase III study protocol in addition to the final analysis.

    Mr. Griffith continued: "We are also excited about the potential of our other two ProTides in the clinic.  We recently presented initial PK data from part one of NuTide:302, the Phase Ib study of NUC-3373 in combination with other agents typically combined with 5-FU in patients with advanced colorectal cancer.  We believe NUC-3373 has significant commercial potential as more than 500,000 patients in North America are estimated to receive 5-FU each year.  We also announced non-clinical data on NUC-7738, our ProTide transformation of a novel nucleoside analog, 3'-deoxyadenosine, detailing multiple potential anti-cancer modes of action."

    NuCana also announced that it is prioritizing resources on its two key programs: Acelarin in biliary tract cancer and NUC-3373 in colorectal cancer. Mr. Griffith remarked: "While our ProTides have the potential to become the new standard of care across multiple indications, we need to focus on programs that we believe will deliver the greatest clinical benefit to patients and create the most value for shareholders. In prior studies, Acelarin has generated positive data in patients with ovarian cancer, both as a single agent as well as in combination with carboplatin. We plan to announce data from the ongoing PRO-105 study of single-agent Acelarin in patients with platinum-resistant ovarian cancer in the first half of 2020. However, the advent of PARP inhibitors has changed the treatment landscape for patients with ovarian cancer resulting in a more complex regulatory pathway for single-agent therapy. We have been highly encouraged by the synergy we have observed with Acelarin in combination with platinum agents, both in patients with biliary tract cancer and ovarian cancer. Thus, should we elect to pursue further development of Acelarin in patients with ovarian cancer, we would anticipate combining it with a platinum agent."

    Based on this prioritization of resources, NuCana believes its current cash and cash equivalents will be sufficient to fund its planned operations into the second half of 2021 as compared to its previous expectation of into 2021. In addition to continuing or completing the ongoing clinical studies, NuCana expects its current cash and cash equivalents will enable the following:   

      •  Continuing to run the Phase III study of Acelarin in combination with cisplatin in patients with biliary tract cancer;
      •  Initiating a Phase II/III study of NUC-3373 in combination with other agents for patients with colorectal cancer.

    Mr. Griffith concluded: "We look forward to announcing more data throughout 2020.  We have continued to validate our ProTide technology's ability to transform some of the most widely prescribed chemotherapy agents into what we believe will be more efficacious and safer treatments. With multiple milestones expected across our pipeline, we anticipate a busy and productive 2020 for NuCana."

    Anticipated Milestones

      •  Acelarin is NuCana's ProTide transformation of gemcitabine. In 2020, NuCana expects to:

    • Provide an update on enrollment in the Phase III study of Acelarin combined with cisplatin as a first-line treatment for patients with advanced biliary tract cancer.
    • Report data from the ongoing Phase II study (PRO-105) of single-agent Acelarin for patients with platinum-resistant ovarian cancer.
    • Provide an update on the investigator-sponsored Phase III study (Acelarate) of Acelarin as a first-line treatment compared to gemcitabine for patients with metastatic pancreatic cancer, for which enrollment has been suspended.

      •  NUC-3373 is NuCana's second ProTide in clinical development, a transformation of the active anti-cancer metabolite of 5-FU. In 2020, NuCana expects to:

    • Report data from the ongoing Phase Ib study (NuTide:302) of NUC-3373 in patients with advanced colorectal cancer and establish the recommended Phase II dose of NUC-3373 in combination with other agents with which 5-FU is typically combined, including leucovorin, oxaliplatin and irinotecan.
    • Contingent on regulatory guidance and other factors, initiate a Phase II/III study of NUC-3373 in combination with other agents for patients with colorectal cancer.
    • Report data from the ongoing Phase I study (NuTide:301) of NUC-3373 in patients with advanced solid tumors.

      •  NUC-7738 is NuCana's ProTide transformation of a novel nucleoside analog, 3'-deoxyadenosine. In 2020, NuCana expects to: 

    • Report data from the Phase I study (NuTide:701) of NUC-7738 in patients with advanced solid tumors.

    About Biliary Tract Cancer

    Biliary tract cancer, including cholangiocarcinoma, gallbladder and ampullary carcinoma, is cancer originating in the bile duct, a vessel that transports bile from the liver to the gall bladder and small intestine. Approximately 178,000 new cases of biliary tract cancer are diagnosed each year worldwide, with more than 18,000 of those diagnoses in the United States.  There are currently no agents approved for the treatment of biliary tract cancer; however, the worldwide standard of care in biliary tract cancer patients with locally advanced or metastatic disease is the combination of gemcitabine and cisplatin. Patients receiving this regimen have a median overall survival of 11.7 months.

    About Colorectal Cancer

    Colorectal cancer is a cancer that starts in the colon or the rectum.  In the United States, approximately 145,000 new cases of colorectal cancer and 51,000 deaths due to the disease are expected in 2019. Worldwide, there were over 1.8 million new colorectal cancer cases in 2018, and the global burden is expected to increase to more than 2.2 million new cases and 1.1 million deaths annually by 2030. Most systemic therapies for colorectal cancer include 5-FU, typically in combination with other therapeutic agents such as oxaliplatin or irinotecan. 5-FU remains the single most prescribed compound for the treatment of colorectal cancer.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents. Acelarin is currently being evaluated in four clinical studies, including a Phase III study for patients with biliary tract cancer, a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with platinum-resistant ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with advanced colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the amount and sufficiency of the Company's current cash and cash equivalents to fund its planned operations into the second half of 2021, the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.


    Unaudited Condensed Consolidated Statements of Operations

               
      For the three months ended
    September 30,
      For the nine months ended
    September 30,
               
      2019 2018   2019 2018
       
      (in thousands, except per share data)
      (unaudited)
      £ £   £ £
    Research and development expenses (4,845) (3,333)   (14,551) (12,196)
    Administrative expenses (1,423) (957)   (4,231) (3,599)
    Net foreign exchange gains 1,227 706   1,191 1,765
    Operating loss (5,041) (3,584)   (17,591) (14,030)
    Finance income 252 297   867 739
    Loss before tax (4,789) (3,287)   (16,724) (13,291)
    Income tax credit 912 771   3,020 3,063
    Loss for the period (3,877) (2,516)   (13,704) (10,228)
               
               
    Basic and diluted loss per share (0.12) (0.08)   (0.42) (0.32)
               


    Unaudited Condensed Consolidated Statements of Financial Position

      September 30,
     2019
    December 31,
    2018
      (in thousands)
      (unaudited)
      £ £
    Assets    
    Non-current assets    
    Intangible assets 3,838 3,122
    Property, plant and equipment 795 427
    Deferred tax asset 28 47
      4,661 3,596
    Current assets    
    Prepayments, accrued income and other receivables 5,907 2,354
    Current income tax receivable 7,284 4,263
    Cash and cash equivalents 58,091 76,972
      71,282 83,589
         
    Total assets 75,943 87,185
    Equity and liabilities    
    Capital and reserves    
    Share capital and share premium 80,832 80,715
    Other reserves 61,722 59,692
    Accumulated deficit (72,347) (58,813)
    Total equity attributable to equity holders of the Company 70,207 81,594
         
    Non-current liabilities    
    Provisions 26 26
    Lease liability 247 -
      273 26
         
    Current liabilities    
    Trade payables 2,155 2,455
    Payroll taxes and social security 136 127
    Lease liability 190 -
    Accrued expenditure 2,982 2,983
      5,463 5,565
         
    Total liabilities 5,736 5,591
         
    Total equity and liabilities 75,943 87,185
         


    Unaudited Condensed Consolidated Statements of Cash Flows

      For the nine months ended
    September 30,
      2019 2018
      (in thousands)
      (unaudited)
      £ £
    Cash flows from operating activities    
    Loss for the period (13,704) (10,228)
    Adjustments for:    
    Income tax credit (3,020) (3,063)
    Amortization and depreciation 522 261
    Finance income (867) (739)
    Share-based payments 2,191 1,494
    Net foreign exchange gains (1,228) (1,808)
      (16,106) (14,083)
    Movements in working capital:    
    Increase in prepayments, accrued income and other receivables (3,593) (2)
    (Decrease) increase in trade payables (300) 1,416
    Increase in payroll taxes, social security and accrued expenditure 8 878
    Movements in working capital (3,885) 2,292
    Cash used in operations (19,991) (11,791)
    Net income tax received 20 1,905
    Net cash used in operating activities (19,971) (9,886)
    Cash flows from investing activities    
    Interest received 915 694
    Payments for property, plant and equipment (29) (205)
    Payments for intangible assets (988) (928)
    Net cash used in investing activities (102) (439)
    Cash flows from financing activities    
    Payments for lease liabilities (146) -
    Proceeds from issue of share capital 117 182
    Net cash (used in) from financing activities (29) 182
    Net decrease in cash and cash equivalents (20,102) (10,143)
    Cash and cash equivalents at beginning of period 76,972 86,703
    Effect of exchange rate changes on cash and cash equivalents 1,221 1,791
    Cash and cash equivalents at end of period 58,091 78,351
         

    For more information, please contact:

    NuCana plc
    Hugh S. Griffith
    Chief Executive Officer
    +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    +1 339-970-2843

    RooneyPartners
    Marion Janic
    +1 212-223-4017

    View Full Article Hide Full Article
  26. NUC-3373: Favorable Pharmacokinetic Profile Demonstrated

    NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway

    BOSTON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced results from two of its clinical stage ProTides, NUC-3373 and NUC-7738, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.

    NuCana presented interim data from the Phase Ib NuTide:302 study in patients with advanced colorectal cancer confirming the previously reported favorable pharmacokinetic profile of NUC-3373. The anti-cancer mechanism of action of NUC-3373 has been previously observed in non-clinical studies, which NuCana believes further…

    NUC-3373: Favorable Pharmacokinetic Profile Demonstrated

    NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway

    BOSTON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced results from two of its clinical stage ProTides, NUC-3373 and NUC-7738, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.

    NuCana presented interim data from the Phase Ib NuTide:302 study in patients with advanced colorectal cancer confirming the previously reported favorable pharmacokinetic profile of NUC-3373. The anti-cancer mechanism of action of NUC-3373 has been previously observed in non-clinical studies, which NuCana believes further supports the biological advantages of NUC-3373 over 5-FU. NUC-3373 is a ProTide transformation of 5-fluorouracil (5-FU), one of the most widely prescribed anti-cancer agents, and is currently being investigated in two clinical studies (NuTide:301 and NuTide:302).

    Hugh S. Griffith, NuCana's Chief Executive Officer, said: "Our aim is to replace 5-FU as the backbone of treatment for patients with colorectal cancer, so we are excited about these data. The next stage of NUC-3373's development will investigate NUC-3373 in patients with advanced colorectal cancer in combination with oxaliplatin and irinotecan."

    NUC-7738, NuCana's third ProTide to enter the clinic, is a transformation of 3'-deoxyadenosine (3'-dA). Six patients have received NUC-7738 to date in the Phase I NuTide:701 study. In non-clinical studies of NUC-7738, NuCana has observed additional anti-cancer mechanisms of action to those previously reported for 3'dA. Significantly higher levels of anti-cancer metabolites are generated inside cancer cells than with 3'-dA, causing increased cell injury. Furthermore, the non-clinical data demonstrated that NUC-7738 activates AMPK, which may inhibit the mTOR pathway, resulting in further cancer cell death.

    Mr. Griffith added: "Our early clinical experience with NUC-7738 has been encouraging and we look forward to sharing further data as the study progresses." 

    Details of NuCana's poster presentations at AACR-NCI-EORTC are as follows:

    Abstract Title:  Inhibition of thymidylate synthase by the ProTide NUC-3373 (Abstract #CO59, Poster #59)
    SESSION: Poster Session C: Therapeutic Agents- Other
    DATE: Tuesday, October 29, 2019, 12:30 p.m. – 04:00 p.m. EDT
    LOCATION:  Level 2, Hall D

    Abstract Title:  NUC-7738, a novel ProTide transformation of 3'-deoxyadenosine, activates AMPK and kills renal cancer cells (Abstract #C122, Poster #122)
    SESSION: Poster Session C: Tumor Suppressors
    DATE: Tuesday, October 29, 2019, 12:30 p.m. – 04:00 p.m. EDT
    LOCATION: Level 2, Hall D

    Additional details can be found on the AACR website.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents.  Acelarin is currently being evaluated in three clinical studies, including a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with ovarian cancer and a Phase III study for patients with metastatic pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with advanced colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine or cordycepin) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the NuTide:301, NuTide:302 and NuTide:701 clinical studies; the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrolment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company's goals with respect to the development and potential use, if approved, of each of its product candidates; and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith
    Chief Executive Officer
    NuCana plc
    Tel: +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    Tel: +1 339-970-2843

    RooneyPartners
    Marion Janic
    Tel: +1 212-223-4017

    View Full Article Hide Full Article
  27. EDINBURGH, United Kingdom, Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Morgan Stanley 17th Annual Global Healthcare Conference in New York, NY.

    Event:  Morgan Stanley 17th Annual Global Healthcare Conference
    Presentation Date: Wednesday, September 11, 2019
    Presentation Time: 10:30 AM EDT

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer…

    EDINBURGH, United Kingdom, Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Morgan Stanley 17th Annual Global Healthcare Conference in New York, NY.

    Event:  Morgan Stanley 17th Annual Global Healthcare Conference
    Presentation Date: Wednesday, September 11, 2019
    Presentation Time: 10:30 AM EDT

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents.  Acelarin is currently being evaluated in three clinical studies, including a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with ovarian cancer and a Phase III study for patients with pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with advanced colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine or cordycepin) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies;  and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith
    Chief Executive Officer
    NuCana plc
    Tel: +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    Tel: +1 339-970-2843

    RooneyPartners
    Marion Janic
    Tel: +1 212-223-4017

    View Full Article Hide Full Article
  28. EDINBURGH, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at Citi's 14th Annual Biotech Conference in Boston on September 5th, 2019.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited…

    EDINBURGH, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at Citi's 14th Annual Biotech Conference in Boston on September 5th, 2019.

    About NuCana plc

    NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.  While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Our most advanced ProTide candidates, Acelarin and NUC-3373, are new chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two widely used chemotherapy agents.  Acelarin is currently being evaluated in three clinical studies, including a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with ovarian cancer and a Phase III study for patients with pancreatic cancer for which enrollment has been suspended. NUC-3373 is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors and a Phase Ib study for patients with advanced colorectal cancer. Our third ProTide, NUC-7738, is a transformation of a novel nucleoside analog (3'-deoxyadenosine or cordycepin) and is in a Phase I study for patients with advanced solid tumors.

    Forward-Looking Statements

    This press release may contain "forward‐looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company's planned and ongoing clinical studies for the Company's product candidates and the potential advantages of those product candidates, including Acelarin, NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies;  and the utility of prior non-clinical and clinical data in determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of the Company's Annual Report on Form 20-F for the year ended December 31, 2018 filed with the Securities and Exchange Commission ("SEC") on March 7, 2019, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward‐looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

    For more information, please contact:

    Hugh S. Griffith
    Chief Executive Officer
    NuCana plc
    Tel: +44 131 357 1111

    Westwicke, an ICR Company
    Chris Brinzey
    Tel: +1 339-970-2843

    RooneyPartners
    Marion Janic
    Tel: +1 212-223-4017

    View Full Article Hide Full Article